Welcome to our dedicated page for Haleon plc SEC filings (Ticker: HLNCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haleon plc’s SEC filings document foreign-issuer reports covering capital structure, treasury-share activity, and financing disclosures. Recent Form 6-K reports include transactions in own shares under a buyback programme, ordinary-share and voting-rights totals, and notices used for ownership-notification calculations under FCA disclosure rules.
The filings also cover listing particulars for the Euro Medium Term Note programme of Haleon UK Capital plc and Haleon Netherlands Capital B.V., guaranteed by Haleon. Company descriptions in the reports identify Haleon as a consumer health company with product categories across oral health, vitamins and supplements, pain relief, respiratory health, digestive health, and therapeutic skin health.
Haleon plc purchased 1,500,000 ordinary shares under the second tranche of its buyback programme announced 31 July 2025. The shares were bought on 15 September 2025 on the London Stock Exchange/CBOE (UK)/CXE and the company intends to hold the purchased shares as treasury shares.
After settlement the company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 4,001,961 are held as treasury shares, leaving 8,948,351,687 ordinary shares with voting rights. The announcement points investors to a full trade breakdown at the provided link and to Haleon's investor website for details.
Haleon plc announced on 15 September 2025 that it purchased 997,991 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Of the purchased shares, 23,788 will be cancelled and 974,203 will be held as treasury shares. After settlement the company's registered share capital is 8,952,353,648 ordinary shares of each, with 2,501,961 held as treasury shares and 8,949,851,687 shares with voting rights.
The announcement notes a full trade breakdown is available via the provided RNS link and on the company's investor website.
Haleon plc announced the purchase and cancellation of 273,737 ordinary shares of each under the second tranche of its share buyback programme. The trades reported relate to executions on 11 September 2025, totaling 273,737 shares with an average price shown as 364.1267 (per the trade breakdown). After settlement, registered share capital is 8,952,377,436 ordinary shares, with 1,527,758 held in treasury, leaving 8,950,849,678 ordinary shares with voting rights. The company provided a full breakdown of individual trades via a public link and noted the announcement does not constitute an offer for securities.